Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

CAR-T cell therapy: current limitations and potential strategies

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Hurdles to breakthrough in CAR T cell therapy of solid tumors

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

Current Clinical Application of the CAR-T Cell Therapy

Bright future or blind alley? CAR-T cell therapy for solid tumors

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

CAR T cell therapy: Current limitations and advancements in treating solid tumors

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

Optimising CAR T therapy for the treatment of solid tumors

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy